Vikram Premkumar, MD

Director of Hematologic Oncology @HolyNameMedCtr. Proud product of @ColumbiaCancer @TulaneMedicine @DukeMedicine @Cornell. Views are my own.

[Vikram Premkumar, MD @vjp8]

Excited and honored to take part in this international collaboration of venetoclax in RR #AL #Amyloidosis with giants in the field @SLentzsch @vsanchorawala @awechalekar @MyelomaDrKapoor @SandyWong02111 @Rfonsi1 @JoshuaRichterMD. High VGPR/CR in t(11;14) and in dara-refractory

[Vikram Premkumar, MD @vjp8]

@RosvoglouReport He’s the candidate I wanted all along. Offensive coach with high upside. We need a reason for optimism

[Thomas Morstead @thomasmorstead]

Next jersey is for my #Saints family.
This jersey is game worn (from 2014 I think).
RETWEET TO WIN!

Will announce winner at start of 3rd quarter.
Thanks for helping raise awareness and money for @TeamGleason
#PuntForALS

[Vikram Premkumar, MD @vjp8]

@thomasmorstead I’ll take a saints one thanks!

[Lil Wayne WEEZY F @LilTunechi]

I hate the cheating azz chiefs

[Vikram Premkumar, MD @vjp8]

@nick_underhill @nick_underhill you think big enough role to flex Blackshear over Kendre? FF championship over here

[Vikram Premkumar, MD @vjp8]

@nick_underhill Loved the decision but should have been a draw to Kendre. He was eating up chunk plays the whole final drive

[Vikram Premkumar, MD @vjp8]

@rajshekharucms @bdermanmd @BloodCancerTalk @DrRakeshPopat Yes I wouldn’t offer quad induction for HR SMM. These data makes me most likely to recommend revlimid or dara monotherapy (prefer dara due to tolerability) given the clear OS benefit. Excited to listen to hear people’s thoughts on your excellent podcast, great work as always

[Vikram Premkumar, MD @vjp8]

@rajshekharucms @bdermanmd Agreed then if your point is that the decision should be between full induction therapy vs. Dara monotherapy for HR SMM. I don’t think that the data supports a watch and wait approach for HR SMM

[Vikram Premkumar, MD @vjp8]

@rajshekharucms @bdermanmd Similarly, continuous maintenance therapy was largely adopted as SOC due to OS benefit which may not exist in the setting of newer therapies. In absence of an RCT showing no OS benefit it remains SOC. The burden is to prove there is no OS benefit in the setting of quad induction

[Vikram Premkumar, MD @vjp8]

@rajshekharucms @bdermanmd The curves clearly separate and the patients were allowed to receive dara in later lines of therapy which make the OS benefit all the more impressive.

Also, I do think if properly consented (which we must always do) the majority of patients would pick the top survival curve

[Vikram Premkumar, MD @vjp8]

@rajshekharucms @Drjhoffmanmiami @VincentRK @Mohty_EBMT @AaronGoodman33 @thanosdimop @NEJM Excellent thread! There’s no OS benefit in the GRIFFIN trial though so I don’t think saying patients not receiving dara upfront once newly diagnosed is the explanation for the OS benefit seen in AQUILA. There are two trials showing OS in high risk SMM, tough to argue against IMO

[Vikram Premkumar, MD @vjp8]

@bdermanmd I agree with the principle however this is not the first trial showing OS benefit. Now in the dara era it’s hard to ignore this IMO. Especially when dara monotherapy is so well tolerated

[Vikram Premkumar, MD @vjp8]

@Jmarksloan Dara Ven Dex (possibly with bortezomib) vs DaraCyBorD in frontline t(11;14) AL could be very informative in this population

[Vikram Premkumar, MD @vjp8]

Enjoying the talks at #ASH24 and especially proud of my fraternity brother @Matt_Cortese for an excellent oral presentation on multiomics in post-venetoclax treated CLL cells. Not for college days alone!

[Vikram Premkumar, MD @vjp8]

@A_kamara6 Thank you captain. You a loyal

[Vikram Premkumar, MD @vjp8]

@nick_underhill 🐍

[Vikram Premkumar, MD @vjp8]

@thomasmorstead Saints love you and miss you. When it’s all said and done come sign and hang it up with us

[Vikram Premkumar, MD @vjp8]

@RossJacksonNOLA You picked the saints to finish 3rd in the division. Breaking my heart Ross!